Publications by authors named "Marc Theoret"

Claim this Profile
U
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.
Nina Kim, E Dianne Pulte, Lori A Ehrlich, Alexei C Ionan, Spencer Haupert, Marc Theoret

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs.
Wei Gao, Jiang Liu, Cynthia J Musante, Hao Zhu, Matthew Thompson, Marc Theoret

Clin Pharmacol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti-PD-1-Based Immunotherapy.
Lianne Hu, Chaohong Fan, Peter Bross, Asha Das, Elin S Cho, Marc R Theoret

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy.
Cara A Rabik, Shu Wang, Ritu Chadda, Donna Przepiorka, Jonathon Vallejo, Marc R Theoret

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine learning reveals distinct T-cell receptor clusters in plasma cell dyscrasias compared to healthy controls.
David G Coffey, Yong Zhang, Elizabeth Hill, Frank Cross, Reena Philip, Marc R Theoret

PLoS One· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy.
Robert Q Le, Kamar Godder, Jingyan Wang, Justin S Collazo, Robyn Konicki, Marc R Theoret

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.
Ashley C Woods, E Dianne Pulte, Xin Wang, Jonathon Vallejo, Ritu Chadda, Marc R Theoret

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma.
Kristen Britton, Upendra Mahat, Nicholas C Richardson, Million Tegenge, Qianmiao Gao, Marc R Theoret

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology.
Laura A Levit, Mirat Shah, Mark J Ratain, Elizabeth Garrett-Mayer, Atiqur Rahman, Marc Theoret

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.
Poornima Sharma, Xue Lin, Zhenzhen Xu, Bindu Kanapuru, Marc R Theoret

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better.
Kristin M Wessel, Nicole Drezner, Stacy S Shord, Mirat Shah, Marc R Theoret

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Mirat Shah, Ting-Yu Chen, Gwynn Ison, Mallorie H Fiero, Hui Zhang, Marc R Theoret

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The BCR-SEQC initiative.
Rittika Mallik, Rebecca Kusko, Andrea C Baines, Reena Philip, Marc R Theoret

Nat Immunol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis.
Asma Dilawari, Mori J Krantz, Ilynn Bulatao, Hee-Koung Joeng, Marc Neilson, Marc Theoret

Ann Noninvasive Electrocardiol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation.
Ashley C Woods, Kelly J Norsworthy, Moran Choe, Brenda J Gehrke, Haiyan Chen, Marc R Theoret

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas.
Maryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu, Lisa R Rodriguez, Susan Jin, Marc R Theoret

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.
Andrea C Baines, Bindu Kanapuru, Jay Zhao, Lauren S L Price, Nan Zheng, Marc R Theoret

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
Anthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes, Marc Theoret

Blood· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.
Gulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan, Haiyan Chen, Shwu-Luan Lee, Marc R Theoret

Clin Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding.
Jorge E Cortes, Elisabetta Abruzzese, Elyce H Cardonick, Sonia Hernández-Díaz, Jamie Gutierrez, Marc R Theoret

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Collection and Analysis of Overall Survival Data.
Lisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, Anup K Amatya, George D Demetri, Marc R Theoret

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Acute Myeloid Leukemia in the Community Setting.
Taha Al-Juhaishi, Servillano Dela Cruz, Rohan Gupta, Gina Keiffer, Vicki A Morrison, Marc R Theoret

Oncologist· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani, Marc Theoret

Oncologist· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.
Kavita Natrajan, Megha Kaushal, Bindu George, Bindu Kanapuru, Marc R Theoret

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia.
Robert Q Le, Donna Przepiorka, Haiyan Chen, Yuan Li Shen, E Dianne Pulte, Marc R Theoret

Blood· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis